Medicamentos para prevenir las cefaleas migrañosas en ... - marchioli

Medicamentos para prevenir las cefaleas migrañosas en los niños
Characteristics of included studies
Interventions
Outcomes
Notes
Allocation concealment
Study
Methods
Participants
Interventions
Outcomes
A: 4-week baseline, then 1-week run-in with placebo, then 10 weeks placebo, then
1-week washout, then 1 week placebo, then 10 weeks placebo, then 1-week washout,
then taught self-hypnosis and followed for 12 weeks.
B: 4-week baseline, then 1-week run-in with propranolol 3 mg/kg/day in 3 divided doses,
then 10 weeks propranolol, then 1-week washout, then 1-week placebo run-in, then
10 weeks placebo, then 1-week washout, then taught self-hypnosis and followed for
12 weeks.
C: 4-week baseline, 1-week run-in with placebo, 10 weeks placebo, 1-week washout,
1-week run-in with propranolol, 10 weeks propranolol, 1-week washout, taught
self-hypnosis and followed for 12 weeks.
Subjective and objective scoring system and frequency.
Since all patients underwent self-hypnosis training during the same period (not via
random allocation to treatment order) we did not further analyse the results for selfhypnosis.
No significant effect on outcomes when using propranolol.
5 withdrawals. 2 - during drug phase (reasons unknown); 3 - during self-hypnosis.
Adverse events: Not reported.
Subjective scoring system = (1 x number of mild headaches + 2 x number of moderate
headaches + 3 x number of severe headaches)/total number of headaches.
Objective scoring system = 1 point for each drug taken during acute attack, vomiting,
sleeping to relieve pain, missed school day, and duration of 3-4 hours; 2 points for a
headache lasting 6 hours or more. Total points/total number of headaches.
B
Pothmann 1987
Randomised, double-blind, drug-drug comparison, parallel-group.
Randomisation not described. Method of blinding not described.
Migraine defined as: Simple migraine - intermittent, often unilateral, with nausea and/or
vomiting and no other symptoms.
Classical migraine - intermittent, often unilateral, with nausea and/or vomiting and
neurological deficits. Complicated migraine - intermittent, recurrent, unilateral headaches
with nausea and/or vomiting and neurological symptoms that last longer than headaches.
Symptomatic treatment permitted (no rules described). 2 non-compliers. Method used
to ascertain compliance not reported.
30 randomised. 7 withdrawals.
Groups A (14 patients) and B (15 patients) were comparable for age, height, weight,
and sex.
14/29 males. Age range: 7 to 17 years.
A: Flunarizine 5 mg (< 40 kg) or 10 mg (> 40 kg) for 8 weeks.
B: ASA 100 mg (< 40 kg) or 200 mg (> 40 kg) for 8 weeks.
Frequency, duration, and symptomatic treatment.
No variability data provided. Investigators reported no significant difference between
drugs.
Página 26
Copyright © John Wiley & Sons Ltd. Usado con permiso de John Wiley & Sons, Ltd.